> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Helix L-DOS47 Study in Pancreatic Cancer
- URL: https://www.fdaweb.com/fda-oks-helix-l-dos47-study-in-pancreatic-cancer/
- Published: 2019-08-08T12:00:00.000Z
- Updated: 2026-09-15T01:42:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144728

FDA has authorized a Helix BioPharma IND to begin a Phase 1b/2 study of L-DOS47 and doxorubicin in patients with advanced metastatic pancreatic cancer who have progressed on at least two prior treatment regimens. The Phase 1b will involve a dose escalation safety run-in to determine the appropriate dose to be used in combination with doxorubicin for Phase2, which will evaluate preliminary anti-tumor activity and safety of the maximum tolerated dose, the company says.

L-DOS47 is Helix’s first immunoconjugate based drug candidate, which is designed to use an “innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction,” the company says. It is also being studied in lung cancer patients.